Chart: State Of Delay: CDER's 2006 Statistics
The annual report from the Center for Drug Evaluation and Research has been delayed, but Director Steven Galson has released some statistics on CDER activities in 2006. The final report will include an improved drug safety section based on FDA's response to the Institute of Medicine's evaluation of drug safety issues at the agency. The statistics below include the number of actions taken in 2006, followed by comparable figures for 2005 in parentheses.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth